• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    The Cigna Group filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    9/4/25 4:08:06 PM ET
    $CI
    Medical Specialities
    Health Care
    Get the next $CI alert in real time by email
    falseCigna Group0001739940900 COTTAGE GROVE ROADBLOOMFIELDNYSE00017399402025-09-042025-09-04

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported) September 4, 2025

    The Cigna Group
    (Exact name of registrant as specified in its charter)

    Delaware
    001-38769
    82-4991898
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    900 Cottage Grove Road
    Bloomfield, Connecticut 06002
    (Address of principal executive offices) (Zip Code)

    Registrant’s telephone number, including area code:
    (860) 226-6000

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, Par Value $0.01
    CI
    New York Stock Exchange, Inc.

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐


    Item 1.01  Entry into a Material Definitive Agreement.

    On September 4, 2025, The Cigna Group (the “Company”) completed its offering of $1,000,000,000 in aggregate principal amount of its 4.500% Senior Notes due 2030 (the “2030 Notes”), $1,250,000,000 in aggregate principal amount of its 4.875% Senior Notes due 2032 (the “2032 Notes”), $1,500,000,000 in aggregate principal amount of its 5.250% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 in aggregate principal amount of its 6.000% Senior Notes due 2056 (together with the 2030 Notes, the 2032 Notes and the 2036 Notes, the “Notes”). The Notes were sold pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-289983).

    The Company intends to use the proceeds (i) to repay $2.0 billion of loans outstanding under the Term Loan Agreement, dated as of August 5, 2025, among the Company, the guarantors from time to time party thereto, the banks from time to time party thereto and Bank of America, N.A., as administrative agent, the proceeds of which were used to fund a strategic investment in another company, and (ii) the remainder for general corporate purposes, which may include investments and repayment of indebtedness. Pending such use, the net proceeds may be invested temporarily in short-term, interest-bearing, investment-grade securities or similar assets.

    The terms of the Notes are governed by an Indenture, dated as of September 17, 2018 (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by Supplemental Indenture No. 8 to the Base Indenture, dated as of September 4, 2025 (“Supplemental Indenture No. 8”), between the Company and the Trustee. Supplemental Indenture No. 8 with respect to the Notes (including the forms of the Notes) is filed as Exhibit 4.1 hereto.

    The 2030 Notes will bear interest at a rate of 4.500% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2030. The 2032 Notes will bear interest at a rate of 4.875% per annum, and interest will be payable on March 15 and September 15 of each year, beginning March 15, 2026 until the maturity date of September 15, 2032. The 2036 Notes will bear interest at a rate of 5.250% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2036. The 2056 Notes will bear interest at a rate of 6.000% per annum, and interest will be payable on January 15 and July 15 of each year, beginning January 15, 2026 until the maturity date of January 15, 2056.

    At any time prior to August 15, 2030 in the case of the 2030 Notes, July 15, 2032 in the case of the 2032 Notes, October 15, 2035 in the case of the 2036 Notes and July 15, 2055 in the case of the 2056 Notes, the Company may redeem some or all of the 2030 Notes, 2032 Notes, 2036 Notes or 2056 Notes, respectively, by paying a “make-whole premium” plus accrued and unpaid interest, if any, to the redemption date. At any time on or after August 15, 2030 in the case of the 2030 Notes, July 15, 2032 in the case of the 2032 Notes, October 15, 2035 in the case of the 2036 Notes and July 15, 2055 in the case of the 2056 Notes, the Company may redeem some or all of the 2030 Notes, 2032 Notes, 2036 Notes or 2056 Notes, respectively, by paying a redemption price equal to 100% of the principal amount of the Notes to be redeemed plus accrued and unpaid interest, if any, to the redemption date.

    The Indenture contains customary events of default and certain covenants including with respect to the Company’s ability to incur certain indebtedness secured by liens on common stock of the Company’s designated subsidiaries or to engage in certain consolidation, merger and sale of asset transactions.

    The foregoing description of Supplemental Indenture No. 8 and the Notes does not purport to be complete and is qualified in its entirety by reference to Supplemental Indenture No. 8 (including the forms of the Notes), which is filed as Exhibit 4.1 hereto, and is incorporated herein by reference.

    Item 2.03  Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.


    Item 8.01  Other Events.

    On September 2, 2025, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Citigroup Global Markets Inc., HSBC Securities (USA) Inc. and Morgan Stanley & Co. LLC, as representatives of the underwriters named in Schedule I thereto, with respect to the issuance and sale by the Company of the Notes.

    The Underwriting Agreement contains customary representations, warranties and agreements of the Company, conditions to closing, indemnification rights and obligations of the parties, and termination provisions.

    The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and incorporated by reference herein.

    A copy of the opinion of Davis Polk & Wardwell LLP, counsel to the Company, relating to the legality of the Notes is filed as Exhibit 5.1 hereto.

    Item 9.01  Financial Statements and Exhibits.

    (d)          Exhibits.
    Exhibit No.
     

    Description
    1.1
     
    Underwriting Agreement, dated as of September 2, 2025, by and among The Cigna Group and BofA Securities, Inc., Citigroup Global Markets Inc., HSBC Securities (USA) Inc. and Morgan Stanley & Co. LLC, as representatives of the underwriters named therein.
    4.1
     
    Supplemental Indenture No. 8, dated as of September 4, 2025, between The Cigna Group and U.S. Bank Trust Company, National Association, as trustee.
    5.1
     
    Opinion of Davis Polk & Wardwell LLP.
    23.1
     
    Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1).
    104
     
    Cover Page Interactive Data File (formatted in Inline XBRL).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

       
    THE CIGNA GROUP
         
    Date:
    September 4, 2025
     
    By:
    /s/ Ann M. Dennison
           
    Name:
    Ann M. Dennison
           
    Title:
    Executive Vice President and Chief Financial Officer

    Get the next $CI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CI

    DatePrice TargetRatingAnalyst
    2/6/2025$323.00Outperform → Mkt Perform
    Bernstein
    6/26/2024$400.00Overweight
    Piper Sandler
    5/30/2024$388.00Outperform
    Robert W. Baird
    3/6/2024$393.00Overweight
    Barclays
    2/5/2024$334.00 → $372.00Neutral → Overweight
    Cantor Fitzgerald
    2/5/2024$327.00 → $354.00Sector Perform → Outperform
    RBC Capital Mkts
    2/1/2024$355.00 → $370.00Hold → Buy
    Deutsche Bank
    1/4/2024$330.00 → $372.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $CI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AM Best Assigns Issue Credit Ratings and Indicative Issue Credit Ratings to The Cigna Group

    AM Best has assigned a Long-Term Issue Credit Rating (Long-Term IRs) of "bbb+" (Good) to The Cigna Group's (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI) new senior unsecured notes. In addition, AM Best has assigned indicative Long-Term IRs on the recently filed shelf registration of Cigna. The outlook assigned to these Credit Ratings (ratings) is stable. (Please see below for a detailed list of the Long-Term IRs.) Concurrently, AM Best has withdrawn the ratings on the previous shelf registration that expired. All other ratings of Cigna remain unchanged. The proceeds from the debt issuances are expected to be used to repay $2 billion of loans outstanding under an existing term loan

    9/4/25 12:47:00 PM ET
    $CI
    Medical Specialities
    Health Care

    Evernorth Health Services Announces Investment in Shields Health Solutions

    Investment Further Enhances Evernorth's Participation in Growing Market for Specialty Medicine  BLOOMFIELD, Conn., Sept. 2, 2025 /PRNewswire/ -- Evernorth Health Services ("Evernorth"), a subsidiary of The Cigna Group (NYSE:CI), today announced a $3.5 billion investment in Shields Health Solutions ("Shields" or the "Company"), a leading specialty pharmacy management company. Evernorth's investment coincides with Shields' establishment as a private standalone company upon its acquisition by Sycamore Partners ("Sycamore"), a leading private equity firm based in New York. This follows Sycamore's acquisition of Walgreens Boots Alliance ("WBA"), Shields' previous owner, which closed on August 28,

    9/2/25 7:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Skipping the Dentist? Not Anymore: Cigna Expands Access to Flexible Dental Payments, Driving Meaningful Increases in Preventive Care and Critical Procedures

    Program Now Expanding to 2.8 Million More Members Nationwide COLUMBIA, Mo., Aug. 5, 2025 /PRNewswire/ -- A flexible payment solution from Paytient and Cigna Healthcare® is helping more people get the dental care they need—when they need it—by removing cost as a barrier. New data shows a measurable increase in both preventive care and critical dental procedures among users. Now, the program is expanding to Cigna's mid-market segment, making it available to 2.8 million additional members nationwide. Initially rolled out to large-group clients like Hyatt, Advantage Solutions, and

    8/5/25 9:04:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kurian George

    4 - Cigna Group (0001739940) (Issuer)

    9/3/25 5:20:12 PM ET
    $CI
    Medical Specialities
    Health Care

    EVP & Chief Health Officer Brailer David J covered exercise/tax liability with 290 shares, decreasing direct ownership by 2% to 17,525 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    9/3/25 5:20:09 PM ET
    $CI
    Medical Specialities
    Health Care

    Officer Jones Nicole S exercised 27,430 shares at a strike of $190.79 and sold $8,557,800 worth of shares (28,526 units at $300.00), decreasing direct ownership by 4% to 28,325 units (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    8/19/25 5:15:58 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    SEC Filings

    View All

    The Cigna Group filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Cigna Group (0001739940) (Filer)

    9/4/25 4:08:06 PM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by The Cigna Group

    424B5 - Cigna Group (0001739940) (Filer)

    9/3/25 7:58:42 PM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by The Cigna Group

    424B5 - Cigna Group (0001739940) (Filer)

    9/2/25 9:12:50 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Cigna Group downgraded by Bernstein with a new price target

    Bernstein downgraded The Cigna Group from Outperform to Mkt Perform and set a new price target of $323.00

    2/6/25 7:05:01 AM ET
    $CI
    Medical Specialities
    Health Care

    Piper Sandler initiated coverage on The Cigna Group with a new price target

    Piper Sandler initiated coverage of The Cigna Group with a rating of Overweight and set a new price target of $400.00

    6/26/24 7:28:18 AM ET
    $CI
    Medical Specialities
    Health Care

    Robert W. Baird initiated coverage on The Cigna Group with a new price target

    Robert W. Baird initiated coverage of The Cigna Group with a rating of Outperform and set a new price target of $388.00

    5/30/24 7:35:19 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Financials

    Live finance-specific insights

    View All

    AM Best Assigns Issue Credit Ratings and Indicative Issue Credit Ratings to The Cigna Group

    AM Best has assigned a Long-Term Issue Credit Rating (Long-Term IRs) of "bbb+" (Good) to The Cigna Group's (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI) new senior unsecured notes. In addition, AM Best has assigned indicative Long-Term IRs on the recently filed shelf registration of Cigna. The outlook assigned to these Credit Ratings (ratings) is stable. (Please see below for a detailed list of the Long-Term IRs.) Concurrently, AM Best has withdrawn the ratings on the previous shelf registration that expired. All other ratings of Cigna remain unchanged. The proceeds from the debt issuances are expected to be used to repay $2 billion of loans outstanding under an existing term loan

    9/4/25 12:47:00 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Reports Strong Second Quarter 2025 Results, Reaffirms 2025 Adjusted EPS Outlook

    Total revenues for the second quarter 2025 increased 11% to $67.2 billionShareholders' net income for the second quarter 2025 was $1.5 billion, or $5.71 per shareAdjusted income from operations1 for the second quarter 2025 was $1.9 billion, or $7.20 per shareReaffirms 2025 outlook for adjusted income from operations1,2 of at least $29.60 per share2BLOOMFIELD, Conn., July 31, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported strong second quarter 2025 results, reflecting continued growth and solid performance across its diverse portfolio of businesses. "Listening, adapting, and innovating to meet the evolving needs of our patients, customers, and clients ena

    7/31/25 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group Declares Quarterly Dividend

    BLOOMFIELD, Conn., July 22, 2025 /PRNewswire/ -- The Board of Directors of The Cigna Group (NYSE: CI) today declared a cash dividend of $1.51 per share of its common stock, payable on September 18, 2025 to shareholders of record as of the close of business on September 4, 2025. About The Cigna Group The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and s

    7/22/25 4:33:00 PM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by The Cigna Group

    SC 13G - Cigna Group (0001739940) (Subject)

    11/12/24 9:55:14 AM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by The Cigna Group (Amendment)

    SC 13G/A - Cigna Group (0001739940) (Subject)

    2/13/24 5:02:29 PM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by The Cigna Group (Amendment)

    SC 13G/A - Cigna Group (0001739940) (Subject)

    2/9/24 8:50:20 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    Leadership Updates

    Live Leadership Updates

    View All

    The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors

    BLOOMFIELD, Conn., June 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2. Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an integrated downstream energy company, and MPLX, a diversified master limited partnership formed by MPC. He joined the company in 2017 and previously held the roles of Chief Executive Officer of MPC and Chairman, President and Chief Executive Officer of MPLX. Prior

    6/2/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group's "Community Vitality Project" Donates $75,000 to Nonprofits through Program Encouraging Fitness and Community Engagement

    As part of the company's initiative, thousands of employees logged 280,000 minutes of exercise over nine days Cigna leaders biked to Hartford, Conn.'s Dunkin' Park to host Boys & Girls Clubs members for a Yard Goats baseball game, with surprise appearances by UConn basketball coach and playersBLOOMFIELD, Conn., Sept. 9, 2024 /PRNewswire/ -- The Cigna Group (NYSE:CI) put out a challenge to its workforce this summer, inviting colleagues to join its first-ever Community Vitality Project, a nine-day challenge combining fun, fitness and fundraising. By logging more than 280,000 minutes of fitness activities and awarding their minutes spent moving, The Cigna Group employees helped determine how to

    9/9/24 7:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    The Cigna Group announces leadership changes to continue driving growth

    Brian Evanko to continue as Chief Financial Officer, will serve as new President and CEO of Cigna HealthcareAnn Dennison to join The Cigna Group as Deputy Chief Financial OfficerMike Triplett to retire by end of 2024 and Bryan Holgerson promoted to President of U.S. Commercial for Cigna HealthcareEric Palmer to assume expanded role leading enterprise strategy and corporate development, will continue as President and CEO of Evernorth Health ServicesBLOOMFIELD, Conn., Jan. 17, 2024 /PRNewswire/ -- The Cigna Group (NYSE:CI), a global health company, today announced leadership changes designed to continue accelerating growth across Evernorth Health Services and Cigna Healthcare.

    1/17/24 9:15:00 AM ET
    $CI
    Medical Specialities
    Health Care